Table 2.

Cross-neutralization of the H5N8 NE14 (A) or H5N6 SC14 (B) virus by monoclonal antibodies measured by plaque reduction assay.

A

	Antibody concentration (µg/ml)
Antibody	20	10	5	2.5	1.25	0.625	0.3125	0.15625	0
100F4	0	0	0	0	0	2.7 ± 0.6*	19.3 ± 2.5	59.3 ± 3.5	59.0 ± 7.5
65C6	0	0	0	0	0	8.0 ± 2.0	42.7 ± 5.0	59.3 ± 5.5	59.0 ± 7.5
AVFluIgG01	59.3 ± 4.0	54.3 ± 3.2	53.3 ± 4.2	57.0 ± 4.6	62.3 ± 4.0	56.3 ± 7.4	57.0 ± 3.6	59.3 ± 6.7	59 ± 7.5
AVFluIgG03	54.0 ± 6.1	54.3 ± 4.0	56.7 ± 4.2	58.0 ± 6.2	59.0 ± 6.6	58.3 ± 3.8	57.7 ± 2.5	61.0 ± 2.6	59.0 ± 7.5
FLA5.10	0	0	0	0	0	0	1.0 ± 1.0	4.7 ± 2.5	59.0 ± 7.5
FLD21.140	0	0	0	0	0	0	0.7 ± 0.6	1.0 ± 1.0	59.0 ± 7.5
S139/1	63.7 ± 6.0	56.0 ± 5.3	55.7 ± 4.0	60.7 ± 2.1	59.7 ± 5.7	60.3 ± 1.2	64.3 ± 1.5	60.7 ± 5.1	59.0 ± 7.5
VRC01	55.0 ± 4.0	56.7 ± 1.5	58.7 ± 1.5	62.0 ± 6.2	61.3 ± 3.1	61.7 ± 6.4	61.0 ± 4.6	63 ± 5.6	59.0 ± 7.5
B
100F4	0	0	0	0	1.0 ± 1.7*	11.0 ± 4.6	55.0 ± 4.6	60.0 ± 7.9	62.0 ± 3.5
65C6	0	0	0	0	16.0 ± 3.6	15.0 ± 4.4	27.0 ± 5.2	53.0 ± 3.6	62.0 ± 3.5
AVFluIgG01	65.0 ± 3.6	64.3 ± 6.1	61.7 ± 4.2	66.0 ± 6.0	61.0 ± 6.2	59.0 ± 6.2	63.0 ± 8.5	60.0 ± 9.0	62.0 ± 3.5
AVFluIgG03	63.0 ± 4.4	61.7 ± 3.1	60.0 ± 5.2	60.0 ± 5.3	60.7 ± 5.5	64.0 ± 7.5	62.0 ± 6.9	62.7 ± 3.5	62.0 ± 3.5
FLA5.10	0	0	0	0	9.0 ± 5.2	6.0 ± 5.2	57.0 ± 3.0	54.7 ± 4.9	62.0 ± 3.5
FLD21.140	0	0	0	0	10.0 ± 9.6	19.0 ± 6.9	26.0 ± 8.7	58.3 ± 2.1	62.0 ± 3.5
S139/1	64.7 ± 4.0	65.3 ± 5.5	62.3 ± 2.5	67.3 ± 4.2	59.7 ± 3.8	60.7 ± 3.8	64.0 ± 6.6	63.0 ± 3.6	62.0 ± 3.5
VRC01	59.7 ± 3.1	63.7 ± 2.1	61.0 ± 7.5	63.3 ± 3.2	62.0 ± 2.6	61.3 ± 4.2	63.7 ± 2.1	64.3 ± 5.5	62.0 ± 3.5

^*Mean ± SD of the number of plaques in triplicates.